Hinge Health (NYSE:HNGE) Announces Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Posted by Geri Gentry on Aug 5th, 2026

Hinge Health (NYSE:HNGE – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.31, FiscalAI reports. The business had revenue of $212.82 million during the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The firm’s revenue for the quarter was up 53.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.59 earnings per share.

Here are the key takeaways from Hinge Health’s conference call:

Q2 results exceeded expectations: Revenue grew 53% year over year to $213 million, operating margin expanded to 29%, and free cash flow rose to $100 million, or a 47% margin.
Hinge Health raised its 2026 outlook to $856 million–$860 million of revenue and $236 million–$244 million of operating income, driven primarily by stronger-than-expected enrollment yields.
The company’s platform expansion is gaining traction, with its migraine program reaching more than 450 clients and five million covered lives; it also agreed to acquire Cylinder Health for $105 million to enter gastrointestinal care.
Commercial momentum remains strong, including an enterprise win covering nearly 300,000 lives, SMB lives growth of more than 100% in the first half, and an opt-out partnership expected to add clients beginning in 2027.
Cylinder is currently operating at a loss and will require product integration and investment over the next nine to 24 months, potentially pressuring near-term margins even though management expects it to approach Hinge’s profitability profile within one to two years.

Hinge Health Trading Up 2.9%

Shares of HNGE stock opened at $79.90 on Wednesday. Hinge Health has a 12-month low of $30.08 and a 12-month high of $91.50. The firm’s 50 day moving average is $74.52 and its 200 day moving average is $54.18. The stock has a market capitalization of $6.18 billion, a P/E ratio of -6.47 and a beta of 1.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Needham & Company LLC increased their price target on shares of Hinge Health from $63.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Piper Sandler reiterated an “overweight” rating on shares of Hinge Health in a research note on Wednesday, June 10th. Citizens Jmp lifted their target price on Hinge Health from $80.00 to $96.00 and gave the stock a “market outperform” rating in a report on Monday, July 27th. Morgan Stanley boosted their price target on Hinge Health from $72.00 to $108.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Barclays reaffirmed an “overweight” rating on shares of Hinge Health in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.07.

Get Our Latest Research Report on Hinge Health

Insider Buying and Selling at Hinge Health

In other Hinge Health news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $85.05, for a total transaction of $7,087,556.70. Following the completion of the sale, the chairman directly owned 83,334 shares in the company, valued at approximately $7,087,556.70. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $69.31, for a total value of $2,287,230.00. Following the transaction, the president directly owned 740,897 shares in the company, valued at $51,351,571.07. The trade was a 4.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 3,766,556 shares of company stock worth $290,713,052. Insiders own 18.92% of the company’s stock.

Institutional Investors Weigh In On Hinge Health

Large investors have recently made changes to their positions in the company. Vista Investment Partners LLC purchased a new stake in shares of Hinge Health during the 2nd quarter valued at about $3,468,000. Assenagon Asset Management S.A. purchased a new position in shares of Hinge Health in the second quarter worth approximately $6,867,000. California State Teachers Retirement System grew its position in Hinge Health by 35.2% during the first quarter. California State Teachers Retirement System now owns 19,141 shares of the company’s stock valued at $738,000 after buying an additional 4,986 shares during the period. Estuary Capital Management LP bought a new stake in Hinge Health during the first quarter valued at approximately $15,201,000. Finally, Lazard Asset Management LLC increased its holdings in Hinge Health by 0.6% during the first quarter. Lazard Asset Management LLC now owns 63,705 shares of the company’s stock valued at $2,456,000 after buying an additional 386 shares during the last quarter.

About Hinge Health

(Get Free Report)

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.